NIB continues financing hearing healthcare R&D

The Nordic Investment Bank (NIB) and the Danish global hearing healthcare company Demant A/S agree to a new 7-year loan agreement of DKK 375 million (EUR 49.2 million) to finance the company’s advancement in hearing solutions and technology research and development.

NIB’s loan will co-finance Demant’s research and development programme for the 2021-2022 period. Demant’s R&D focus on hearing healthcare and audio technology. Demant has an extensive and comprehensive R&D programme, partnering with different universities, research centers and companies primarily in Denmark. The Bank has provided a total of five loans to the company since 2015.

Demant is a global leading hearing healthcare company headquartered in Denmark. The William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen. Demant’s offering spans hearing aids, hearing care, diagnostic equipment and services as well as audio technology solutions.

NIB is an international financial institution owned by eight member countries: Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. The Bank finances private and public projects in and outside the member countries. NIB has the highest possible credit rating, AAA/Aaa, with the leading rating agencies Standard & Poor’s and Moody’s.

For further information, please contact
Fridrik Andersen, Senior Banker, Services & Consumer, at +358 10 618 0238, Fridrik.Andersen@nib.int

David Bonilla Rasmusson, Communications Unit, at +358 50 476 3071, David.Rasmusson@nib.int

Tags: